Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19900305 | 0.76 | LRRK2 (0.36) | LRRK2 | |
| SCHEMBL29732895 | 0.70 | ALDH1A1 (0.36) | MEN1KMT2ALRRK2 | |
| SCHEMBL19900326 | 0.70 | ALDH1A1 (0.36) | MEN1KMT2ALRRK2 | |
| SCHEMBL8388467 | 0.67 | LRRK2 (0.36) | LRRK2THRB | |
| SCHEMBL18005388 | 0.67 | TLR9 (0.40) | TLR9TLR7LRRK2 | |
| SCHEMBL24439695 | 0.65 | LRRK2 (0.40) | LRRK2 | |
| SCHEMBL18005390 | 0.64 | MEN1 (0.36) | MEN1KMT2ATHRB | |
| SCHEMBL18029910 | 0.64 | MEN1 (0.36) | MEN1KMT2ATHRB | |
| SCHEMBL18029840 | 0.64 | ALOX5AP (0.41) | TLR9TLR7LRRK2 | |
| SCHEMBL8995823 | 0.63 | LMNA (0.42) | LMNACYP1A2THRBBLMCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3719006-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEUTERATED AND UNDEUTERATED 2-AMINO-PYRIMIDIN-5-OL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES (E.G. OBESITY) | UNIV ARIZONA STATE (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3719006-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEUTERATED AND UNDEUTERATED 2-AMINO-PYRIMIDIN-5-OL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES (E.G. OBESITY) | Arizona Board of Regents on behalf of Arizona State University (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3259254-B1 | DEUTERATED AND UNDEUTERATED 2-AMINO-PYRIMIDIN-5-OL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES (E.G. OBESITY) | UNIV ARIZONA STATE (US) | 2020-07-01 | — | — | EP | disclosed |
| US-10364227-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-07-30 | — | — | US | disclosed |
| US-20180319751-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-11-08 | — | — | US | disclosed |
| WO-2016133959-A9 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-02-22 | — | — | WO | disclosed |
| EP-3259254-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents on behalf of Arizona State University (US) | 2017-12-27 | — | — | EP | disclosed |
| WO-2016133959-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2016-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319751-A1 | THERAPEUTIC COMPOUNDS | SDHA, CYP11B1, CYP11B2 | MEN1 97/4885KMT2A 4565/4885TLR9 4801/4885 |
| US-10364227-B2 | Therapeutic compounds | SDHA, CYP11B1, CYP11B2 | MEN1 97/4885KMT2A 4565/4885TLR9 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.